Prognostic impact of molecular markers in a series of 220 primary glioblastomas
Authors:
- Julie LejeuneJLJulie Lejeune
- Emmanuelle CriniereECEmmanuelle Criniere
- Khe Hoang‐XuanKHKhe Hoang‐Xuan
- Marc SansonMSMarc Sanson
Open Access
Abstract
BACKGROUND: In contrast to oligodendrogliomas, molecular predictors of prognosis have not been consistently found in glioblastomas. However, genetic studies show that glioblastomas consist of several genetic subtypes and raise the possibility that molecular alterations could be predictive of survival.METHODS: A search for loss of heterozygosity (LOH) on chromosome 1p, 9p, 10q, 19q, EGFR (epidermal growth factor receptor), CDK4, and MDM2 (mouse double minute) amplifications, CDKN2A (INK4A/ARF) homozygous deletions, p53 expression, was performed in a series of 220 primary glioblastomas. The molecular alterations were then correlated with each other to identify distinct molecular pathways and with clinical parameters and the course of the disease to identify prognostic markers.RESULTS: Nonrandom associations were found between EGFR amplification and LOH10q, LOH9p, and INK4A/ARF deletion, LOH1p and LOH19q, and MDM2 and CDK4 amplification, whereas mutual exclusions were found between p53 expression and EGFR amplification, LOH 9p/INK4A/ARF homozygous deletion, and MDM2 and CDK4 amplification. Age (P = 4.10−5) and performance status (P = .003) were the main predictors of outcome. In contrast, molecular markers were of limited impact: MDM2 amplification correlated with poor outcome on both univariate and multivariate analysis (P = .01) and EGFR amplification with good prognosis on multivariate analysis (P = .02).CONCLUSION: Despite their limited prognostic impact, the genetic markers investigated here outline distinct molecular pathways involved in glioblastoma tumorigenesis and warrant broader molecular screening. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 33 references indexed in Scilit:
- Genetic Pathways to GlioblastomaCancer Research, 2004
- Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p DeletionsJournal of Clinical Oncology, 2004
- Age-Dependent Prognostic Effects of Genetic Alterations in GlioblastomaClinical Cancer Research, 2004
- Impact of Genotype and Morphology on the Prognosis of GlioblastomaJournal of Neuropathology & Experimental Neurology, 2002
- Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progressionNeurology, 2001
- Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular StudyJournal of Neuropathology & Experimental Neurology, 2001
- Epidermal Growth Factor Receptor Gene Amplification as a Prognostic Marker in Glioblastoma Multiforme: Results of a Meta-AnalysisOncology Research, 2001
- Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System TumorsJournal of Neuropathology & Experimental Neurology, 2000
- The challenge of p53 as prognostic and predictive factor in gliomasCancer Treatment Reviews, 2000
- Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic OligodendrogliomasJNCI: Journal of the National Cancer Institute, 1998